Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + ZJCH-AML in NUP98-positive Pediatric AML
NCT07437170Phase 2Active, not recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in acute myeloid leukemia (AML), sponsored by Children's Hospital, Zhejiang University School of Medicine. Started Jan 2024; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07437170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07437170.